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Abstract
Phenoxyethanol, or 2-phenoxyethanol, has a large spectrum of antimicrobial activity and has been widely used as a
preservative in cosmetic products for decades. It is effective against various Gram-negative and Gram-positive bacteria,
as well as against yeasts, and has only a weak inhibitory effect on resident skin ﬂora. According to the European Scien-
tiﬁc Committee on Consumer Safety, phenoxyethanol is safe for all consumers – including children of all ages – when
used as a preservative in cosmetic products at a maximum concentration of 1%. Adverse systemic effects have been
observed in toxicological studies on animals but only when the levels of exposure were many magnitudes higher (around
200-fold higher) than those to which consumers are exposed when using phenoxyethanol-containing cosmetic prod-
ucts. Despite its widespread use in cosmetic products, phenoxyethanol is a rare sensitizer. It can be considered as one
of the most well-tolerated preservatives used in cosmetic products.
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Introduction
Phenoxyethanol (CAS n. 122-99-6) is an ether and aromatic
alcohol, which is also known as 2-phenoxyethanol, ethylene gly-
col monophenyl ether, phenoxytol, 1-hydroxy-2-phenoxyethane
and (2-hydroxyethoxy) benzene.
It has a large spectrum of antimicrobial activity and is effec-
tive against various Gram-negative (e.g. Pseudomonas aerugi-
nosa) and Gram-positive (e.g. Staphylococcus aureus)1 bacteria,
as well as against yeasts (e.g. Candida albicans).2,3 Phenoxyetha-
nol exerts its antimicrobial activity by uncoupling oxidative
phosphorylation from respiration and by competitively inhibit-
ing malate dehydrogenase.4 It also acts as a bactericidal agent by
increasing the permeability of the cell membrane to potassium
ions and exerts a direct inhibitory effect on microbial DNA and
RNA synthesis.4 Due to its broad antimicrobial activity, phe-
noxyethanol has been used for decades as a preservative in vari-
ous products such as medicines (e.g. in vaccines) and hand
disinfecting biocidal products up to a concentration of 5%,
including products for toddlers.5
Phenoxyethanol exhibits a weaker inhibitory effect on normal
skin-resident bacteria than other cosmetic chemical preservatives
(e.g. methylisothiazolinone, iodopropynyl butylcarbamate,
ethylhexylglycerin and methylparaben6) and is used as a preser-
vative in a large range of rinse-off and leave-on cosmetic prod-
ucts. It is also a fragrance ingredient used in many fragrance
mixtures.3 In a recent study analysing the full ingredient infor-
mation contained in the American Contact Dermatitis Society
database – the Contact Allergen Management Program – for a
large panel of common cosmetic products marketed in the USA
(n = 4737), phenoxyethanol was found in 23.9% (n = 1132) of
the products.7 Moreover, a recent study conducted in Spain
reported that 43.09% of cosmetics sold exclusively in pharma-
cies, 23.29% of cosmetics sold in supermarkets and
14.1% of cosmetics from herbal shops, contained
phenoxyethanol.8
Some glycol ethers, such as ethylene glycol ethyl ether or
ethylene glycol methyl ether, have been shown to have toxic
effects on reproduction and have been banned in Europe [see
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European Regulation (EC) No 1272/2008]. However, the
chemical and physical properties of phenoxyethanol differ
from those of these glycol ethers (e.g. it is not volatile) and
phenoxyethanol was not classified as a reproductive toxicant
in EC No 1272/2008 unlike some other glycol ethers. Never-
theless, some concerns about its safety were raised due to its
assimilation to the whole glycol ether family. Furthermore,
controversial claims that phenoxyethanol has an effect on the
blood and liver, and that it disrupts endocrine activity, have
been a matter of public debate and received media attention.
According to Commission Regulation 2018/605 amending
Plant Protection Regulation No. 1107/2009, a substance
should be considered as having endocrine disrupting activity
in humans if: it shows an adverse effect in an intact organism
or its progeny leading to functional changes; it has an endo-
crine mode of action (anti-oestrogenic, androgenic or anti-
androgenic activity, alters steroidogenesis or has thyroid and
anti-thyroid hormone activity); or the adverse effect is a con-
sequence of the endocrine mode of action. In June 2015, the
high-throughput Endocrine Disruptor Screening Program of
the U.S. Environmental Protection Agency (US-EPA) deter-
mined that phenoxyethanol had no oestrogenic activity.9 In
addition, although phenoxyethanol may be a rare sensitizer, it
has not been classified as a skin sensitizer by the European
Chemicals Agency (ECHA).
In Europe, preservatives allowed for use in cosmetic prod-
ucts are regulated by Annex V of Cosmetics Regulation (EC)
No. 1223/2009.10 According to this regulation, phenoxyethanol
is authorized as a preservative in cosmetic formulations at a
maximum concentration of 1% (Annex V/29). The safety pro-
file of phenoxyethanol as a preservative in cosmetic products
was assessed at the European level by the Scientific Committee
on Consumer Safety (SCCS) in 2016.3 This assessment led the
committee to conclude that phenoxyethanol was safe for con-
sumers – including children of all ages – when used as a
preservative in cosmetic products at a maximum concentra-
tion of 1%. However, the French National Agency for the
Safety of Medicines and Health Products (ANSM) recom-
mended that phenoxyethanol should not be used as a preser-
vative in cosmetic products intended for application on the
nappy area (including wipes) of children aged under 3 years.11
This recommendation was based on a worst-case aggregate
exposure calculation covering the five most used cosmetic
products in French children. When wipes and cosmetic prod-
ucts intended for application to the nappy area were excluded
from exposure calculation, the risk assessment conducted by
the ANSM indicated that phenoxyethanol used at a maximum
concentration of 1% in cosmetic products was also safe for
children aged under 3 years.
The objective of this report was to review the safety of phe-
noxyethanol, taking into account the opinion of the SCCS and
published scientific literature.
Data searching methods
The SCCS conducted a review of available safety data on phe-
noxyethanol, which included both data from peer-reviewed sci-
entific journals and safety data from unpublished studies carried
out by cosmetic product manufacturers, often at the request of
the SCCS. These data, as well as other data from ANSM assess-
ments, were used in the current review. In addition, an updated
search of safety data on phenoxyethanol was performed using
PubMed. The following search terms were used: ‘phe-
noxyethanol’ OR ‘Ethylene glycol monophenyl ether’ OR ‘(2-
hydroxyethoxy) benzene’ OR ‘glycol ether’ OR ‘phenoxyacetic
acid’. As the most recent publication used in the SCCS opinion
study was dated November 2015, the date limits for publications
used in our review were set as 1 November 2015 to 31 May 2019.
Articles were screened by two reviewers based on titles and
abstracts, and only those dealing with the safety of phe-
noxyethanol were selected.
Review of safety data
Dermal/percutaneous absorption
The percutaneous absorption of phenoxyethanol at concentra-
tions of 0.2 and 1% was evaluated in vitro using rat and human
skin samples in two studies.3,12 The study of Roper et al.12 con-
tained some deficiencies and was not considered as relevant by
the SCCS.
The results of an unpublished study (Vincent CM and Marty JP
(2002), as cited by the SCCS 3) showed that in vitro dermal
absorption of phenoxyethanol in humans was high and rapid,
regardless of its concentration in the formulation tested. After
24 h of exposure, very small amounts (<0.1%) remained in the
various layers of the skin and most of the phenoxyethanol was
recovered in the receptor fluid, indicating that phenoxyethanol
does not bind to or accumulate in the skin. The dermal absorption
of phenoxyethanol (i.e. the total amount of phenoxyethanol in the
receptor fluid, dermis and epidermis) after a 24-h period for a for-
mulation containing 1% phenoxyethanol was 37%  10% for the
rinse-off products and 78%  7% for the leave-on products.
Bioavailability
Numerous in vivo kinetic studies using oral and topical routes
have been conducted in animals,3,12–15 as well as in humans.14
These studies showed that phenoxyethanol is rapidly absorbed,
distributed, metabolized and excreted. It can be metabolized
either in the skin or in the liver; however, its metabolism rate is
higher in the liver. The major metabolite of phenoxyethanol, 2-
phenoxyacetic acid, is formed in a two-step oxidation process by
cytosolic alcohol dehydrogenase and aldehyde dehydrogenase.12
In humans, regardless of the route of exposure – i.e. after
topical exposure in clinical trials with adults14 or preterm
babies,16 or after oral administration in a study conducted in an
adult male14 – phenoxyethanol is excreted in urine, primarily as
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2-phenoxyacetic acid. This metabolite was found in higher con-
centrations in in vitro experiments using liver S9 homogenates
of human donors than in other species (hu-
man > rat > mouse > rabbit).3,12 None of these studies allowed
the systemic bioavailability of phenoxyethanol to be determined
in humans.3
In 2015, a research team17 used a physiologically based phar-
macokinetic (PBPK) model to predict the systemic availability of
phenoxyethanol in rats and humans. However, the results of this
PBPK model were not considered to be relevant by the SCCS3
due to the following reasons:
• Results for rats obtained using the PBPK model were under-
estimated compared to those obtained from a ‘real’ study
conducted in rats15;
• Results in humans could not be compared with ‘real’ data
[observed area under the curve (AUC) of either phe-
noxyethanol or 2-phenoxyacetic acid compared to their
predicted AUC], thus limiting the validity of this PBPK
model.
In conclusion, phenoxyethanol is almost completely absorbed
through skin (78%  7% for the leave-on products) and metab-
olized either by the skin or by the liver into its major metabolite
2-phenoxyacetic acid. This metabolite is primarily found in
human urine. The systemic availability of phenoxyethanol, and
its metabolite, cannot be determined in humans from the data
that are currently available.
Repeated dose toxicity
The repeated dose toxicity of phenoxyethanol has been exten-
sively studied in animals via the inhalation (rats), oral (mice and
rats) and dermal routes (rabbits).3 A brief review of the results
of the studies considered as relevant in terms of their method-
ological approach by the SCCS (i.e. OECD guidelines and Good
Laboratory Practices compliant studies) is reported below (sum-
marized in Table 1).
Inhaled route Rats (five animals per sex per dose) exposed to
phenoxyethanol concentrations of 0, 40, 200 and 1000 mg/m³
via the inhaled route for 6 h/day and 5 days/week for 14 days
showed no treatment-related systemic effects (Table 1). Local
irritation of the respiratory system was the only effect reported
(BASF AG (2007), Report No.: 3610498/01187, unpublished
study as cited by the SCCS3).
Oral route In a study conducted in rabbits (six females in the
control group and three females per dose group) exposed to a
10-day treatment via the oral route, signs of haematotoxicity
were reported at doses of 100 mg/kg bodyweight (bw)/day and
above13 (Table 1).
In a 90-day repeated dose toxicity study conducted in rats (10
animals per sex per dose), exposure via the oral route had effects
on red blood cell parameters and led to histopathological
changes in the kidney and urinary bladder at high doses, i.e. the
lowest observed adverse effect level of 687 mg/kg bw/day for
males and 1000 mg/kg bw/day for females [MHLW Japan Bioas-
say Research Centre (2003), Study No. 459, unpublished study
as cited by the SCCS3] (Table 1).
In mice (10 animals per sex per dose), results of a 90-day
repeated dose toxicity study carried out via the oral route
showed some changes in red blood cell parameters suggestive of
mild anaemia, and some effects on the liver such as decreases in
cholesterol and phospholipid concentrations at phenoxyethanol
doses of 765 mg/kg bw/day for males and 948 mg/kg bw/day for
females [MHLW Japan Bioassay Research Centre (2003), Study
No. 460, unpublished study as cited by the SCCS3] (Table 1).
Topical route Three studies conducted in rabbits exposed via
the topical route were identified: two published and one unpub-
lished (Table 1). In a 90-day topical route toxicity study in rab-
bits, no treatment-related effects were observed on bodyweight
or organ weight, on haematological or clinical parameters, or on
gross or histopathological features up to the highest dose tested
of 500 mg/kg bw/day.13 Similarly, in a developmental toxicity
pilot study, no systemic effects were reported up to a maximum
tested dose of 1000 mg/kg bw/day (Dow Chemical USA, Report
No.: K-000111011, unpublished study as cited by the SCCS3). In
contrast, another developmental toxicity study reported signs of
haematotoxicity at 600 mg/kg bw/day and above.18
In conclusion, the systemic effects – such as haematological
and liver effects – observed in these animal studies occurred after
oral exposure to high doses of phenoxyethanol. However, the
oral route of administration and the high doses used in these
animal studies are not relevant for evaluation of the toxicity of
phenoxyethanol used as a cosmetic ingredient.
Haematological effects were also reported after exposure
through the topical route in one study conducted in rabbits.
These effects were also observed at high doses (600 mg/kg bw/
day and above), which are not relevant for toxicity evaluations
of phenoxyethanol used under cosmetic conditions. Indeed,
based on the SCCS report and considering that a consumer may
use a set of cosmetic products containing the same preservative,
such as rinse-off and leave-on products, the aggregate value for
phenoxyethanol at a maximum concentration of 1% is 2.69 mg/
kg bw/day. Therefore, the haematological effects reported in the
developmental study conducted in rabbits were observed at a
dose approximately 200-fold higher than that used by con-
sumers.
Additionally, the skin of rabbits is known to be more perme-
able than that of humans19 and the rate of metabolism of phe-
noxyethanol in rabbits is lower than that of other species,
particularly humans (human > rat > mouse > rabbit; Dow
Chemical USA, Report No.: K-000111011, unpublished study as
cited by the SCCS3). Phenoxyethanol (and not its metabolite 2-
phenoxyacetic acid) is responsible for the haematotoxicity
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observed in animal studies.3 Overall, the available data indicate
that the rabbit is the most sensitive species tested due to its sus-
ceptibility to haematotoxic effects. This increased sensitivity may
be explained, for the most part, by the limited capacity of this
species for metabolizing phenoxyethanol compared to other spe-
cies, including humans. In addition, in vitro studies have shown
that rabbit red blood cells are more sensitive to phenoxyethanol
than those of other species, including humans.3,13 Consequently,
the haematological effects reported in rabbits should not be con-
sidered as relevant for toxicity assessments in humans.
Mutagenicity/genotoxicity
The mutagenic potential of 2-phenoxyethanol was first tested
in vitro using the Ames test. Phenoxyethanol did not show any
mutagenic activity in bacteria at concentrations up to 5000 lg/
plate, with or without rat liver microsomal activation (BASF
AG, 2002, Report No.: 712402, unpublished study as cited by the
SCCS3). Similarly, negative results were obtained in mammalian
cells when phenoxyethanol, up to a maximum concentration of
approximately 10 mmol/L, was tested for its ability to induce
gene mutations at the Hprt locus (BASF AG, 2002, Report No.:
712401, unpublished study as cited by the SCCS3). Furthermore,
no clastogenic effect was observed in structural chromosome
aberration tests in vitro (Dow Chemical USA, Report No.: K-
000111-018, unpublished study as cited by the SCCS3).
Micronucleus and chromosome aberration tests performed
in vivo in mice did not provide evidence of any clastogenic
potential (BASF AG, 2002, Report No.: 712403, unpublished
study as cited by the SCCS3). Finally, phenoxyethanol induced
no DNA damage in an UDS test in rats and also showed no evi-
dence of genotoxicity (BASF AG, 2002, Report No.: 712404,
unpublished study as cited by the SCCS3).
Based on these studies, the SCCS considered that 2-phenox-
yethanol had no mutagenic potential in vivo and was not geno-
toxic to humans.
Long-term toxicity and carcinogenicity studies
The carcinogenic potential of phenoxyethanol was assessed in
two carcinogenicity studies conducted using the oral route in
rats [MHLW Japan Bioassay Research Centre (2007), Study No.
0497, unpublished study as cited by the SCCS3] and mice
[MHLW Japan Bioassay Research Centre (2007), Study No.
0498, unpublished study as cited by the SCCS3]. In the study
carried out in rats (50 animals per sex per dose), mild-to-moder-
ate toxic effects were reported on the kidneys in males at the
high dose of 510 mg/kgbw/day. These effects were not reported
in females at any of the doses tested.
In the study conducted in mice (50 animals per sex per dose),
reduced gains in bodyweight, as well as decreases in some chemi-
cal parameters (phospholipids and cholesterol), were observed
at intermediate and high doses (>898 mg/kg bw/day), but the
changes relative to controls were in part slight and showed noT
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clear dose–response relationship and were not clearly related to
the administration of phenoxyethanol.
No carcinogenic effects, such as the presence of neoplastic
lesions, were reported in these two studies (Table 2).
Reproductive effects in animals
As stated in the introduction, phenoxyethanol is not classified as
a reproductive toxic substance in EC No 1272/2008. In the ani-
mal studies reported by the SCCS – a two-generation reproduc-
tive toxicity study conducted in mice and two developmental
toxicity studies carried out in rabbits – no effects on reproduc-
tive and developmental parameters were observed.3
Endocrine disruption potential
There were no data included in the SCCS opinion on the endo-
crine activity of phenoxyethanol.3 However, the June 2015 high-
throughput Endocrine Disruptor Screening Program conducted
by the US-EPA determined that phenoxyethanol has no oestro-
genic activity.9 Moreover, a systematic review has been recently
published studying the association between exposure to non-
persistent chemicals in consumer products and fecundability.20
Amongst the 12 studies included in this review, only one obser-
vational study conducted by Garlantezec et al.21 in 2013 dealt
with glycol ethers, including phenoxyethanol (Table 3). More
recently, the same team also recently published two other obser-
vational studies on glycol ethers, including phenoxyethanol.22,23
The three original articles cited above21–23 report the results
of observational longitudinal French studies in two large
mother–child cohorts, the PELAGIE cohort and the Eden
cohort, aiming to determine the relationship between occupa-
tional and non-occupational exposure to several glycol ethers,
including phenoxyethanol, and specific outcomes related to
ovarian function in a random sample of women. The PELAGIE
cohort included 3421 pregnant women recruited before
19 weeks of gestation between 2002 and 2006 and followed up
to the end of pregnancy. The EDEN cohort included 2002 preg-
nant women, before their 24th week of amenorrhoea, from 2003
to 2006 (Table 3). Time to pregnancy was assessed using a self-
administered questionnaire, and exposure to glycol ethers was
assessed by measuring metabolite levels, including phenoxyacetic
acid the primary metabolite of phenoxyethanol, in a random
sample of urine specimens.
Garlantezec et al.21 first evaluated the relationship between
exposure to glycol ethers and time to pregnancy in 519 women
through a self-administered questionnaire filled in at inclusion.
The results showed a statistically significant association between
high urine phenoxyacetic acid concentrations and a longer time
to pregnancy (Table 3). With the exception of phenoxyacetic
acid, no associations between other glycol ether metabolites and
a longer time to pregnancy were observed. As the study of Gar-
lantezec et al.21 is the only study that showed such results, Hip-
well et al.20 concluded in their review that it was not possible to
draw a final conclusion without additional data. Furthermore,
this kind of observational epidemiological study is prone to con-
siderable scientific inconsistencies and weaknesses. Firstly, these
studies are susceptible to recall bias and the self-reported infor-
mation may be incomplete or inaccurate. Moreover, the mea-
sured endpoint ‘time to pregnancy’ is a so-called fickle endpoint
Table 2 Summary of carcinogenic studies of phenoxyethanol based on SCCS3
References Species, strain and
number of animals
Route of
exposure
Doses Duration of
exposure
Main ﬁndings
MHLW Japan Bioassay
Research Centre (2007),
Study No. 0497,
unpublished study as
cited by the SCCS3
Rat F344 DuCrlCrlj
50 animals per sex
per dose
Oral 0, 2500, 5000 and
10 000 ppm in
drinking water
corresponding to
124, 249 and
510 mg/kg bw/day
in males and 191,
380 and 795 mg/kg
bw/day in females
104 days Increased incidence of mild-to-moderate
urothelial hyperplasia and mild papillary
mineralization and necrosis in the
kidneys in males at 10 000 ppm
No histopathological ﬁndings in the
kidney in females
Increases in liver enzymes (AST, ALT) in
males at 10 000 ppm
Increased bilirubin and decreased
triglycerides in females at 10 000 ppm,
without any histopathology ﬁndings in
the liver
MHLW Japan Bioassay
Research Centre (2007),
Study No. 0498,
unpublished study as
cited by the SCCS3
Mouse B6D2F1 Crlj
50 animals per sex
per dose
Oral 0, 5000, 10 000 and
20 000 ppm in
drinking water
corresponding to
468, 898 and
1701 mg/kg bw/day
in males and 586,
1072 and 2058 mg/
kg bw/day in
females
104 days Decreases in cholesterol and
phospholipids at ≥10 000 ppm and
decreases in triglycerides at 20 000 ppm
in males
Decreases in bodyweight gain at
≥10 000 ppm in males and at 20 000
ppm in females
ALT, alanine aminotransferase; AST, aspartate aminotransferase; bw, bodyweight.
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and the baseline was not clear, making it impossible to interpret
any changes. Also, the risk cannot be estimated directly and the
odds ratio (OR) is only an approximation of the relative risk in
the underlying population. Only one urine sample was collected,
and this unique sample would not have been representative of
the all-day exposure to glycol ethers as they are cleared very
rapidly from the body. Finally, as stated by the authors,21 it
could not be excluded that phenoxyacetic acid exposure was
actually a proxy marker to exposure to other chemicals, or even
that their results were due to chance or to uncontrolled con-
founding factors that need to be evaluated in future studies.
In a second publication,22 the same team studied the associa-
tion between in utero exposure to glycol ethers and hormone
levels in the cord blood of 338 women included in the PELAGIE
cohort. Cord blood samples were collected after delivery, and
the levels of 13 sex steroid hormones and the sex hormone-bind-
ing globulin (SHBG) were evaluated. The results showed that
phenoxyacetic acid was associated with lower levels of SHBG
and of some other steroid hormones assessed in boys: significant
linear decreases in dehydroepiandrosterone [DHEA; b (95%
CI) = 0.09 (0.16; 0.01)] and 17-alpha-hydroxy-pregneno-
lone [17-Preg; b (95% CI) = 0.10 (0.18; 0.02)] levels, as
well as ‘small departures from linearity’ for delta-5-androstene-
diol (D5), were reported. Furthermore, an association between
phenoxyacetic acid and small increases in the levels of SHBG
and 16-alpha-hydroxy-DHEA (16-DHEA) was observed
amongst girls. However, this study was prone to similar scientific
inconsistencies and weaknesses as those reported for the study of
Garlantezec et al.21 The ANSM assessed this study in its recent
opinion11 and concluded that further research is needed to reach
a conclusion on these results.
The third study was a case–control study nested in the two
joint PELAGIE and EDEN cohorts. Its results showed that there
was no association between urinary concentrations of phenoxy-
acetic acid and cryptorchidism or hypospadias.23
In conclusion, only three publications were identified and all
were part of the same cohort study. These three reports did not
reveal that phenoxyethanol had any endocrine disrupting poten-
tial. The first study did not show any association between phe-
noxyacetic acid, the primary metabolite of phenoxyethanol, and
cryptorchidism or hypospadias. The two other studies did not
provide any evidence for a plausible association between phe-
noxyacetic acid and changes in SHBG, androgenic and oestro-
genic activities in newborns. Concerning the thyroid effects,
there are no indications from the animal studies of any effect
involving the thyroid hormone pathway. Furthermore, the
ANSM concluded that these data cannot be used to assess the
endocrine disruption potential of phenoxyethanol.11
Neurological effects
Phenoxyethanol was not reported to have any neurotoxic effects
in subchronic animal studies, irrespective of the administration
route used (see section on repeated dose toxicity). The SCCS
reported an observational occupational study conducted in three
women working in a fish hatchery and using phenoxyethanol to
anaesthetize fish.24 These women experienced neurological
Table 3 Summary of endocrine disruption effects assessed in human studies
Author, year Study design Number
of women
Outcome Results
Garlantezec et al.,
201321
Residential
retrospective
519 Time to pregnancy assessed
using a self-administered
questionnaire
Statistically signiﬁcant association between high urine
phenoxyacetic acid concentrations (≥ 1.38 mg/L with a
fOR = 0.70; 95%; CI = 0.52–0.95, compared to the
lowest concentration < 0.14 mg/L) and a longer time to
pregnancy
Warembourg
et al., 2018a22
Residential
prospective
338 Concentrations of 13 sex
steroid hormones and SHBG
in cord blood samples
collected after delivery
Lower levels of SHBG and some other steroid hormones
assessed in boys
Association between phenoxyacetic acid and signiﬁcant
linear decreases in DHEA levels [b (95% CI) = 0.09
(0.16; 0.01)], 17-Preg levels [b (95% CI) = 0.10
(0.18; 0.02)] and D5 levels (‘small departures from
linearity’) in boys
Association between phenoxyacetic acid and small
increases in the levels of SHBG, as well as 16-alpha-
hydroxy-DHEA (16-DHEA), in girls
Warembourg
et al., 2018b23
Nested case–
control study
115 Cryptorchidism or
hypospadias reported in
forms of routine clinical
examination for congenital
anomalies
No association between urinary concentrations of
phenoxyacetic acid and cryptorchidism or hypospadias
Note: Measurement mode of phenoxyethanol exposure in all these studies was performed by dosing its metabolite, phenoxyacetic acid, in a single urine
sample.
16-DHEA, 16-alpha-hydroxy-DHEA; 17-Preg, 17-alpha-hydroxy-Pregnenolone; CI, conﬁdence interval; D5, delta-5-androstenediol; DHEA, dehy-
droepiandrosterone; OR, odds ratio; SHBG, sex hormone-binding globulin.
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effects such as headaches or grogginess. However, no conclu-
sions can be drawn from this study because of its numerous lim-
itations: the low number of participants (only three women), a
failure to report the concentration of phenoxyethanol used to
anaesthetize the fish, the lack of measurements of the dosage of
phenoxyethanol or its metabolite in blood or urine, and the
absence of a description of the neuropsychological test used to
assess cognitive impairment.
A recent ancillary study of the PELAGIE cohort25 (see section
Reproductive effects in animals for more details) assessed the
neurocognitive abilities of the 6-year-old children of a random
sample of mothers using the Wechsler Intelligence Scale for
Children IV (WISC) and the Developmental Neuropsychological
Assessment (NEPSY). The results showed no association
between NEPSY and WISC – Working Memory Index scores
and exposure to phenoxyacetic acid. A significantly lower WISC
– Verbal Comprehension Index (VCI) score – was observed for
children whose mothers were in the highest tertile of the urinary
phenoxyacetic acid concentrations measured. Nevertheless, the
relationship between prenatal urinary phenoxyacetic acid con-
centrations and lower WISC – VCI scores – was not linear as an
inverse correlation was observed when participants with urinary
phenoxyacetic acid concentrations below the median were con-
sidered. Additionally, the same limitations as those reported for
the three studies discussed above21–23 can be applied to this
study – i.e., these results may be due to chance or to uncon-
trolled confounding factors.
Local effects
Eye irritation Phenoxyethanol has been shown to produce signs
of eye irritation in vivo, when administered undiluted in three
rabbits, with a maximal irritation 72 h after instillation of the
test substance (BASF AG (1983), Report No.: 83/143, unpub-
lished study as cited by SCCS).3
Skin irritation Undiluted phenoxyethanol, which is never used
in cosmetics, has been shown to induce mild-to-moderate irrita-
tion in animals studies conducted in rabbits and guinea pigs.3,26
In humans, no local or systemic effects were observed after the
use of phenoxyethanol on injured skin: patients with superficial
wounds or with burns.27,28 Additionally, phenoxyethanol was
well tolerated in a study where the skin of premature neonatal
infants was disinfected with an aqueous solution containing
0.1% octenidine and 2% phenoxyethanol.16 However, a recent
retrospective study conducted in premature infants with extre-
mely low birthweights in Germany found that some signs of skin
irritation, such as erythema or skin erosion, occurred with a
topical antiseptic solution containing both 0.1% octenidine and
phenoxyethanol. However, the concentrations in this antiseptic
were not reported and it is difficult to link these effects exclu-
sively to phenoxyethanol, because octenidine may also cause
serious cutaneous complications.29 Nevertheless, premature
infants are at higher risk of developing skin irritation due to
their immature skin barrier.
The ANSM described other studies in its assessment and no
irritation reactions were observed in humans.26
Allergy Sensitization animal studies (maximization tests) con-
ducted in Guinea pigs did not show any sensitization reactions
following skin exposure to phenoxyethanol.3,26 In humans, the
overall frequency of sensitization reactions attributed to phe-
noxyethanol is very low (0.1–0.24%). The SCCS reported the
studies described below3,26,30 (summarized in Table 4).
In a large surveillance study conducted between 1996 and
2009 in Germany, Switzerland and Austria, the frequency of sen-
sitization to phenoxyethanol tested at a concentration of 1% in a
patch-test population of 6932 subjects was 0.24%.31 The authors
concluded that phenoxyethanol could be regarded as an extre-
mely rare allergen, if as an allergen at all.31 The same authors
had also conducted a previous study, between 1990 and 1994,
and showed that the frequency of positive patch tests to phe-
noxyethanol was 0.1% of the 11 120 patients patch-tested.32 The
SCCS also reported a small study carried out in Spain,33 which
showed that 0.2% of patch-tested patients showed a positive
reaction to 1% 2-phenoxyethanol.
Recently, in 2012, Scognamiglio et al. reviewed patch test
studies with phenoxyethanol and found that positive reactions
ranged from zero to 0.2%.34
The SCCS and the ANSM reported a small number of cases
(n = 8) of skin allergy attributed to phenoxyethanol after topical
contact with cosmetic products, medicines and metal-working
Table 4 Summary of studies related to the frequency of allergies attributed to phenoxyethanol2,6,7,11 reported by the SCCS and the
ANSM
Author, year Country Period of study Number of patch-
tested patients
Frequency of sensitization
to phenoxyethanol (%)
Schnuch et al., 1998 32 Germany, Switzerland and
Austria
Between 1990 and 1994 6932 0.24
Bordel-Gomez et al., 2010 33 Spain Between 2000 and 2005 1092 0.2
Schnuch et al., 201131 Germany, Switzerland and
Austria
Between 1996 and 2009 11 120 0.1
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fluids.35–42 Amongst these, three cases had contact urticaria and
the remaining cases had contact dermatitis.35,36,39 In all three
cases of contact urticaria, the manifestations appeared minutes
after application of the cosmetic products and no respiratory
symptoms were reported. A serum sample from one of the
patients was tested for immunoglobulin E (IgE) antibodies
against phenoxyethanol, and the presence of specific IgE could
not be confirmed.35 According to the authors,35 both an IgE-
mediated mechanism and non-immunologic contact urticaria
were possible causes. However, as phenoxyethanol is a hapten,
protein-binding and elicitation of symptoms within a few min-
utes are unlikely, suggesting a non-immunologic pathogenesis.
Contact urticaria43 and contact dermatitis44 were also reported
in two cases after the use of phenoxyethanol-containing ultra-
sound gels. Open tests43 and patch tests44 on these subjects were
positive for phenoxyethanol, suggesting that phenoxyethanol
was the allergen in both cases.
Recent data from the scientific literature revealed that neg-
ative results for patch tests with phenoxyethanol had been
obtained in 11 patients tested in Finland.45 In addition, a
review of contact allergens in natural hair dyes concluded
that of all the cases of contact allergy to preservatives con-
tained in these products, only very few cases were attributed
to phenoxyethanol.46
Although phenoxyethanol is present in a large variety of
rinse-off and leave-on cosmetic products,7,8 allergy reactions –
such as contact urticaria – are rare. Phenoxyethanol is one of the
most well-tolerated preservatives used in cosmetic products, and
it is not classified as a sensitizer by the ECHA.
Conclusion
Based on the currently available safety data, phenoxyethanol can
be considered as safe when used as a preservative in cosmetic
products at a concentration of up to 1%. Adverse systemic
effects were observed in animal studies only at levels of exposure
which were magnitudes higher than those that consumers would
be exposed to when using cosmetic products containing phe-
noxyethanol. Despite its widespread use in cosmetic products,
phenoxyethanol is only a rare sensitizer and it can be considered
as one of the most well-tolerated preservatives used in cosmetic
products.11
The SCCS concluded in 2016 that phenoxyethanol is safe for
all consumers – including children of all ages – when used as a
preservative in cosmetic products at a maximum concentration
of 1%.3 The only restriction given by the French ANSM is not to
use phenoxyethanol as a preservative in cosmetic products
intended for application to the nappy area (including wipes) of
infants and children aged under 3 years.30
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